US3852316A - Prostaglandin f2 {62 {0 analogs - Google Patents
Prostaglandin f2 {62 {0 analogs Download PDFInfo
- Publication number
- US3852316A US3852316A US00273316A US27331672A US3852316A US 3852316 A US3852316 A US 3852316A US 00273316 A US00273316 A US 00273316A US 27331672 A US27331672 A US 27331672A US 3852316 A US3852316 A US 3852316A
- Authority
- US
- United States
- Prior art keywords
- pgf
- compounds
- analogs
- acid
- pge
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229960001342 dinoprost Drugs 0.000 title 1
- PXGPLTODNUVGFL-YNNPMVKQSA-N prostaglandin F2alpha Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O PXGPLTODNUVGFL-YNNPMVKQSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 58
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 150000003180 prostaglandins Chemical class 0.000 abstract description 24
- 229940094443 oxytocics prostaglandins Drugs 0.000 abstract description 19
- 125000004432 carbon atom Chemical group C* 0.000 abstract description 13
- DZUXGQBLFALXCR-UHFFFAOYSA-N (+)-(9alpha,11alpha,13E,15S)-9,11,15-trihydroxyprost-13-en-1-oic acid Natural products CCCCCC(O)C=CC1C(O)CC(O)C1CCCCCCC(O)=O DZUXGQBLFALXCR-UHFFFAOYSA-N 0.000 abstract description 6
- 230000000144 pharmacologic effect Effects 0.000 abstract description 4
- 208000010110 spontaneous platelet aggregation Diseases 0.000 abstract description 3
- 230000000767 anti-ulcer Effects 0.000 abstract 1
- 230000006698 induction Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000002253 acid Substances 0.000 description 30
- 238000000034 method Methods 0.000 description 26
- 150000003839 salts Chemical class 0.000 description 12
- -1 amine cations Chemical class 0.000 description 11
- 239000000376 reactant Substances 0.000 description 11
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 10
- 230000009467 reduction Effects 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 230000037396 body weight Effects 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 150000007513 acids Chemical class 0.000 description 8
- 150000001412 amines Chemical class 0.000 description 8
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 150000001768 cations Chemical class 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 150000002148 esters Chemical class 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 6
- 238000005886 esterification reaction Methods 0.000 description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 6
- 229910052751 metal Inorganic materials 0.000 description 6
- 239000002184 metal Substances 0.000 description 6
- 241000282414 Homo sapiens Species 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 5
- 230000008512 biological response Effects 0.000 description 5
- 230000032050 esterification Effects 0.000 description 5
- 238000001704 evaporation Methods 0.000 description 5
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000001772 blood platelet Anatomy 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 238000010253 intravenous injection Methods 0.000 description 4
- 208000037805 labour Diseases 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 125000005907 alkyl ester group Chemical group 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 210000003754 fetus Anatomy 0.000 description 3
- 210000004907 gland Anatomy 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 238000010255 intramuscular injection Methods 0.000 description 3
- 239000007927 intramuscular injection Substances 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- PXGPLTODNUVGFL-JZFBHDEDSA-N prostaglandin F2beta Chemical class CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H](O)[C@@H]1C\C=C/CCCC(O)=O PXGPLTODNUVGFL-JZFBHDEDSA-N 0.000 description 3
- 210000002460 smooth muscle Anatomy 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- RXYPXQSKLGGKOL-UHFFFAOYSA-N 1,4-dimethylpiperazine Chemical compound CN1CCN(C)CC1 RXYPXQSKLGGKOL-UHFFFAOYSA-N 0.000 description 2
- VVJKKWFAADXIJK-UHFFFAOYSA-N Allylamine Chemical compound NCC=C VVJKKWFAADXIJK-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 2
- JQVDAXLFBXTEQA-UHFFFAOYSA-N dibutylamine Chemical compound CCCCNCCCC JQVDAXLFBXTEQA-UHFFFAOYSA-N 0.000 description 2
- 229960002179 ephedrine Drugs 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 229910017053 inorganic salt Inorganic materials 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 210000004914 menses Anatomy 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 2
- 229960001802 phenylephrine Drugs 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000012746 preparative thin layer chromatography Methods 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 229960000278 theophylline Drugs 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- PFJVIOBMBDFBCJ-UHFFFAOYSA-N (1z)-1-diazobutane Chemical compound CCCC=[N+]=[N-] PFJVIOBMBDFBCJ-UHFFFAOYSA-N 0.000 description 1
- LDDMACCNBZAMSG-BDVNFPICSA-N (2r,3r,4s,5r)-3,4,5,6-tetrahydroxy-2-(methylamino)hexanal Chemical compound CN[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO LDDMACCNBZAMSG-BDVNFPICSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- QFUSOYKIDBRREL-NSCUHMNNSA-N (e)-but-2-en-1-amine Chemical compound C\C=C\CN QFUSOYKIDBRREL-NSCUHMNNSA-N 0.000 description 1
- BTUGGGLMQBJCBN-UHFFFAOYSA-N 1-iodo-2-methylpropane Chemical compound CC(C)CI BTUGGGLMQBJCBN-UHFFFAOYSA-N 0.000 description 1
- PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 1
- RQEUFEKYXDPUSK-UHFFFAOYSA-N 1-phenylethylamine Chemical compound CC(N)C1=CC=CC=C1 RQEUFEKYXDPUSK-UHFFFAOYSA-N 0.000 description 1
- LJDSTRZHPWMDPG-UHFFFAOYSA-N 2-(butylamino)ethanol Chemical compound CCCCNCCO LJDSTRZHPWMDPG-UHFFFAOYSA-N 0.000 description 1
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 description 1
- IOAOAKDONABGPZ-UHFFFAOYSA-N 2-amino-2-ethylpropane-1,3-diol Chemical compound CCC(N)(CO)CO IOAOAKDONABGPZ-UHFFFAOYSA-N 0.000 description 1
- JCBPETKZIGVZRE-UHFFFAOYSA-N 2-aminobutan-1-ol Chemical compound CCC(N)CO JCBPETKZIGVZRE-UHFFFAOYSA-N 0.000 description 1
- MWGATWIBSKHFMR-UHFFFAOYSA-N 2-anilinoethanol Chemical compound OCCNC1=CC=CC=C1 MWGATWIBSKHFMR-UHFFFAOYSA-N 0.000 description 1
- ANGGPYSFTXVERY-UHFFFAOYSA-N 2-iodo-2-methylpropane Chemical compound CC(C)(C)I ANGGPYSFTXVERY-UHFFFAOYSA-N 0.000 description 1
- RGHPCLZJAFCTIK-UHFFFAOYSA-N 2-methylpyrrolidine Chemical compound CC1CCCN1 RGHPCLZJAFCTIK-UHFFFAOYSA-N 0.000 description 1
- HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 description 1
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
- 206010003162 Arterial injury Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241001631457 Cannula Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 101150065749 Churc1 gene Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
- MHZGKXUYDGKKIU-UHFFFAOYSA-N Decylamine Chemical compound CCCCCCCCCCN MHZGKXUYDGKKIU-UHFFFAOYSA-N 0.000 description 1
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 1
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- RPNUMPOLZDHAAY-UHFFFAOYSA-N Diethylenetriamine Chemical compound NCCNCCN RPNUMPOLZDHAAY-UHFFFAOYSA-N 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010055690 Foetal death Diseases 0.000 description 1
- 241000699694 Gerbillinae Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001072332 Monia Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- PHSPJQZRQAJPPF-UHFFFAOYSA-N N-alpha-Methylhistamine Chemical compound CNCCC1=CN=CN1 PHSPJQZRQAJPPF-UHFFFAOYSA-N 0.000 description 1
- AKNUHUCEWALCOI-UHFFFAOYSA-N N-ethyldiethanolamine Chemical compound OCCN(CC)CCO AKNUHUCEWALCOI-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
- 101800000989 Oxytocin Proteins 0.000 description 1
- 102100031951 Oxytocin-neurophysin 1 Human genes 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010050902 Postoperative thrombosis Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102100038239 Protein Churchill Human genes 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000001351 alkyl iodides Chemical class 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- YOUGRGFIHBUKRS-UHFFFAOYSA-N benzyl(trimethyl)azanium Chemical compound C[N+](C)(C)CC1=CC=CC=C1 YOUGRGFIHBUKRS-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 239000003633 blood substitute Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- KMGBZBJJOKUPIA-UHFFFAOYSA-N butyl iodide Chemical compound CCCCI KMGBZBJJOKUPIA-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229940116592 central nervous system diagnostic radiopharmaceuticals Drugs 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- NISGSNTVMOOSJQ-UHFFFAOYSA-N cyclopentanamine Chemical compound NC1CCCC1 NISGSNTVMOOSJQ-UHFFFAOYSA-N 0.000 description 1
- WLXALCKAKGDNAT-UHFFFAOYSA-N diazoethane Chemical compound CC=[N+]=[N-] WLXALCKAKGDNAT-UHFFFAOYSA-N 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- JRBPAEWTRLWTQC-UHFFFAOYSA-N dodecylamine Chemical compound CCCCCCCCCCCCN JRBPAEWTRLWTQC-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 231100001046 intrauterine death Toxicity 0.000 description 1
- 150000004694 iodide salts Chemical class 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229940039009 isoproterenol Drugs 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- HTBVGZAVHBZXMS-UHFFFAOYSA-N lithium;tris[(2-methylpropan-2-yl)oxy]alumane Chemical compound [Li].[Al+3].CC(C)(C)[O-].CC(C)(C)[O-].CC(C)(C)[O-] HTBVGZAVHBZXMS-UHFFFAOYSA-N 0.000 description 1
- 229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- XJINZNWPEQMMBV-UHFFFAOYSA-N n-methylhexan-1-amine Chemical compound CCCCCCNC XJINZNWPEQMMBV-UHFFFAOYSA-N 0.000 description 1
- 239000000133 nasal decongestant Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 238000006053 organic reaction Methods 0.000 description 1
- KVNYFPKFSJIPBJ-UHFFFAOYSA-N ortho-diethylbenzene Natural products CCC1=CC=CC=C1CC KVNYFPKFSJIPBJ-UHFFFAOYSA-N 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
- 229960001723 oxytocin Drugs 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 238000004810 partition chromatography Methods 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- BITYAPCSNKJESK-UHFFFAOYSA-N potassiosodium Chemical compound [Na].[K] BITYAPCSNKJESK-UHFFFAOYSA-N 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- YORCIIVHUBAYBQ-UHFFFAOYSA-N propargyl bromide Chemical class BrCC#C YORCIIVHUBAYBQ-UHFFFAOYSA-N 0.000 description 1
- ZMRUPTIKESYGQW-UHFFFAOYSA-N propranolol hydrochloride Chemical compound [H+].[Cl-].C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 ZMRUPTIKESYGQW-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000002997 prostaglandinlike Effects 0.000 description 1
- WGJJROVFWIXTPA-OALUTQOASA-N prostanoic acid Chemical class CCCCCCCC[C@H]1CCC[C@@H]1CCCCCCC(O)=O WGJJROVFWIXTPA-OALUTQOASA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- GGCZERPQGJTIQP-UHFFFAOYSA-N sodium;9,10-dioxoanthracene-2-sulfonic acid Chemical compound [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-N 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- CBXCPBUEXACCNR-UHFFFAOYSA-N tetraethylammonium Chemical compound CC[N+](CC)(CC)CC CBXCPBUEXACCNR-UHFFFAOYSA-N 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- JJPVWQWOOQYHCB-UHFFFAOYSA-N triethyl(phenyl)azanium Chemical compound CC[N+](CC)(CC)C1=CC=CC=C1 JJPVWQWOOQYHCB-UHFFFAOYSA-N 0.000 description 1
- RKBCYCFRFCNLTO-UHFFFAOYSA-N triisopropylamine Chemical compound CC(C)N(C(C)C)C(C)C RKBCYCFRFCNLTO-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
Definitions
- R is hydrogen, alkyl of one to 8 carbon atoms, inclusive, or a pharmacologically acceptable cation, wherein a is zero or one, wherein n is 2, 3, 4, 5, 6, 7, or 8, wherein m is one, 2, 3, 4, or 5, and wherein indicates attachment of hydroxy to the ring in alpha or beta configuration with' the provisos that the compound contains l8, 19, 20, 2I, or 22 carbon atoms exclusive of R and that the chain does not contain 7 carbon atoms exclusive of R.
- d is 7 'or 8 and p is one, 2, or 3.
- e is 3, 4, or 5.
- XVIII and XXIV,f is 4, 5 or 6 and q is one, 2', or 3.
- t is one or 2.
- v is'one or 2.
- Compounds of formula I wherein indicates an alpha attachment of hydroxy to the ring are analogs of prostaglandin F (PGF, when a is zero and are analogs of prostaglandin F (IPGF a when a is one.
- Compounds of formula 1 wherein indicates a beta attachment of hydroxy to the ring are analogs of prostaglandin F (PGF p when a is zero and are analogs of prostaglandin F 5 (lPGF when a is one.
- PGF a has the following structure:
- Molecules of PGF, PGE, B PGF a and PGF B and of each of the compounds encompassed by formulas l-XXIX each have several centers of asymmetry.
- Formulas l-XXlX are intended to represent o'ptically active compounds each with the same absolute configuration as optically active PGF, obtained from certain mammalian tissues, for example, sheep vesicular glands or human seminal plasma. See, for example, Bergstrom etal., Pharmacol. Rev. 20, l (1968) and references cited therein.
- each ofthe known prostaglandins PGF PGF PGF a and PGF B have carbon atoms.
- a significant characteristic of these known prostaglandins is the seven carbon carboxyl-terminated side chain. Prostaglandins obtained from animal tissues always contain that length of that chain.
- each of the novel prostaglandin analogs encompassed by formulas l-XXIX, exclusive of the possible carbon content of R have a carboxyl-terminated chain shorter or longer than seven carbon atoms.
- novel compounds ofthis invention have the same total nu er of carbon atoms present in the known prostaglandins, while some have fewer and some have more carbon atoms, but in each novel compound, the carboxylterminated chain is different than in the known prostaglandins. It will be observed that compounds of formulas ll-lX each have the same methyl-terminated chain present in the known prostaglandins. Both the methylterminated chain and the carboxyl-terminated chain in compounds of formulas XXXIX differ from those chains in the natural prostaglandins.
- PGF a PGF a PGF, ,3 and PGF B .and their esters and pharmacologically acceptable salts, are extremely potent in causi pg various biological-responses.
- these known prostaglandins are useful to study, prevent, control, or alleviate a wide variety of diseases and undesirable physiological conditions in .birds and mammals, includ- 1 ing humans, useful domestic animals, pets and zoological specimens, and in laboratory animals, for example, mice, rats, rabbits, and monkeys.
- these compounds are useful in mammals, including man, as nasal decongestants.
- the compounds are used in a dose range of about 10 ug. to about 10 mg. per ml. ofa pharmacologically suitable liquid vehicle or as an aerosol spray, both for topical application.
- the PGF and PGF compounds are useful in the treatment of asthma.
- these compounds are useful as bronchodilators or as inhibitors of mediators, such as SRS-A, and histamine which are released from cells activated by an antigen-antibody complex.
- mediators such as SRS-A
- histamine which are released from cells activated by an antigen-antibody complex.
- these compounds control spasm and facilitate breathing in conditions such as bronchial asthma, bronchitis, brochiectasis, pneumonia and emphysema.
- these compounds are administered in a variety of dosage forms, e.g., orally in the form of tablets, capsules, or liquids; rectally in the form of suppositories; parenterally, subcutaneously, or intramuscularly, with intravenous administration being preferred in emergency situations; by inhalation in the form of aerosols or solutions for nebulizers; or by insufflation in the form of powder.
- dosage forms e.g., orally in the form of tablets, capsules, or liquids; rectally in the form of suppositories; parenterally, subcutaneously, or intramuscularly, with intravenous administration being preferred in emergency situations; by inhalation in the form of aerosols or solutions for nebulizers; or by insufflation in the form of powder.
- Doses in the range of about 0.01 to 5 mg. per kg. of body weight are used 1 to 4 times a day, the exact dose depending on the age, weight, and condition of the patient and on the frequency and route
- prostaglandins can be combined advantageously with other anti-asthmatic agents, such as sympathominetics (isoproterenol, phenylephrine, ephedrine, etc.)', xanthine derivatives (theophylline and aminophyllin); and cortico-steroids (ACTH and predinisolone).
- sympathominetics isoproterenol, phenylephrine, ephedrine, etc.
- xanthine derivatives theophylline and aminophyllin
- cortico-steroids ACTH and predinisolone
- the PGF and PGF ,3 compounds are useful whenever it is desired to inhibit platelet aggregation, to reduce the adhesive character of platelets, and to remove or prevent the formation of thrombi in mammals,- including man, rabbits, and rats.
- these compounds are useful in the treatment and prevention of myocardial infarcts, to treat and prevent postoperative thrombosis, to promote patency of vascular the range of 0.004 to about 20 mg. per kg. of body weight per day are used, the exact dose depending on the age, weight, and condition of the patient or animal, and on the frequency and route of administration.
- the PGF (1 and PGF [3 compounds are especially useful as additives to blood, blood products, blood substitutes, and other fluids which are used in artificial extra-corporeal circulation and perfusion ofisolated body portions, e.g., limbs and organs, whether attached to the original body, detached and being preserved or pre' pared for transplant, or attached to a new body.
- body portions e.g., limbs and organs
- aggregated platelets tend to block the blood vessels and portions of the circulation apparatus. This blocking is avoided by the presence of these compounds.
- the compound is added gradually or in single or multiple portions to the circulating blood, to the blood of the donor animal, to the perfused body portion, attached or detached, to the recipient, or to two or all of those at a total steady-state dose of about 0.001 to 10 mg. per liter of circulating fluid. It is especially useful to use these compounds in laboratory animals, e.g., cats, dogs, rabbits, monkeys, and rats, for these purposes in order to develop new methods and techniques for organ and limb transplants.
- the PGF [3 compounds are useful as hypotensive agents to reduce blood pressure in mammals, including man.
- the compounds are administered by intravenous infusion at the rate about 0.01 to about 50 pg. per kg. of body weight per minute or in single or multiple doses of about 25 to 500 pg. per kg. of body weight total per day.
- the PGF B compounds also increase the flow of blood in the mammalian kidney, thereby increasing volume and electrolyte content of the urine. Therefore, these compounds are useful in managing cases of renal disfunction, especially those involving blockage of the renal vascular bed. Illustratively, the compounds are useful to alleviate and correct cases of edema resulting, for example, from massive surface burns, and in the management of shock.
- the compounds are preferably first administered by intravenous injection at a dose in the range 10 to 1000 pg. per kg. of body weight or by intravenous infusion at a dose in the range 0.1 to peg. per kg. of body weight per minute until the desired effect is obtained. Subsequent doses are given by intravenous, intramuscular, or subcutaneous injection or infusion in the range 0.05 to 2 mg. per kg. of body weight per day.
- the PGF a and PGF 5 compounds are useful in place of oxytocin to induce labor in pregant female animals, including man, cows, sheep, and pigs, at or near term, or in pregnant animals with intrauterine death of the fetus from about 20 Weeks to term.
- the compound is infused intravenously at a dose 0.01 to 50 ug. per kg. of body weight per minute until or near the termination of the second stage of labor,
- PGF 0, and PGF [3 compounds are useful for controlling the reproductive cycle in ovulating female mammals, includinghumans and animals such as monkeys, rats, rabbits, dogs, cattle, and the like.
- PGF a for example, is administered systemically at a dose level in the range 0.0] mg. to about 20 mg. per kg. of body weight of the female mammal, advantageously during a span of time starting approximately at the time of ovulation and ending approximately at the time of menses or just prior to menses.
- expulsion of an embryo or a fetus is accomplished by similar administration of the compound during the first third of the normal mammalian gestation period.
- novel PGF a and PGF 3 analogs encompassed by formulas I-XXIX each cause the same biological respouses described above for the corresponding known prostaglandins.
- Each of these new compounds is accordingly useful for the above-described pharmacological purposes, and is used for those purposes in. the same manner as described above.
- PGF for example, PGF; 3 stimulates smooth muscle and also lowers blood pressure at the same low dose.
- these known prostaglandins havean inconveniently short duration of biological activity.
- the novel Formula l-XXIX compounds are substantially more specific with regard to potency in causing prostaglandin-like biological responses, and have a substantially longer duration of biological activity.
- each of these novel prostaglandin analogs is surprisingly and unexpectedly more useful than one of the corresponding above-mentioned known prostaglandins for at least one of the pharmacological purposes indicated above for the latter, because it has a different and narrower spectrum of biological activity than the known prostaglandins, and therefore is more specific in its activity and causes smaller and fewer undesired side effects than when the known prostag landin is used for the.
- novel compounds of this invention are administered effectively orally, sublingually, intravaginally, buccally, or rectally, in addition to the usual intravenous, intramuscular, or subcutaneous injection or infusion methods indicated above for the uses of the known p'rostaglandins. These qualities are advantageous because they facilitate maintaining uniform levels of these compounds in the body with fewer, shorter, or smaller doses, and make possible self-administration by the patient.
- novel PGF (1 and PGF 5 compounds encompassed by formulas l-XXIX are used as described above in the free acid form, in alkyl ester form, or in pharmacologically acceptable salt form.
- ester form any alkyl ester can be used wherein the alkyl moiety contains one to 8 carbon atoms, inolusive, i.e., methyl, ethyl, propyl, butyl, pentyl, hexyl,
- ester be alkyl of one to four carbon atoms, inclusive. Of those alkyl, methyl and ethyl are especially preferred for optimum absorption of the compound by the body or experimental animal system.
- Pharmacologically acceptable salts of these formula l-XXlX compounds useful for the purposes described above are those with pharmacologically acceptable metal cations, ammonium, amine cations, or quaternary ammonium cations.
- Especially preferred metal cations are those derived from the alkali metals, elg., lithium, sodium and potassium, and from the alkaline earth metals, e.g., magnesium and calcium, although cationic forms of other metals, e.g., aluminum, zinc, and iron, are within the scope of this invention.
- amine cations are those derived from primary, secondary, or tertiary amines.
- suitable amines are methylamine, dimethylamine, trimethylamine, ethylamine, dibutylamine, triisopropylamine, N-methylhexylamine, decylamine, dodecylamine, allylamine, crotylamine, cyclopentylamine, 'dicyclohexylamine, benzylamine, dibenzylamine, a-phenylethylamine, ,B-phenylethylamine, ethylenediamine, diethylenetriamine, and like aliphatic, cycloaliphatic, and araliphatic amines containing up to and including about 18 carbon atoms, as well as heterocyclic amines, e.g., piperidine, morpholine, pyrrolidine, piperazine, and lower-alkyl derivatives thereof, e.g.,
- amines containing watersolubilizing or hydrophilic groups e.g., mono-, di-, and triethanolamine, ethyldiethanolamine, N-butylethanolamine, 2-amino-l-butanol, 2-amino-2- ethyl-1,3-propanediol, '2-amino-2-methyl-l-propanol, tris(hydroxymethyl)aminomethane, N- phenylethanolamine, N-(ptert-amylphenyl)diethanolamine, galactamine, N-methylglucamine, N- methylglucosamine, ephedrine, phenylephrine, epinephrine, procaine, and the like.
- mono-, di-, and triethanolamine ethyldiethanolamine
- N-butylethanolamine 2-amino-l-butanol
- Suitable pharmacologically acceptable quaternary ammonium cations are tetramethylammonium, tetraethylammonium, benzyltrimethylammonium, phenyltriethylammonium, and the like.
- the compounds of formulas l-XXIX are administered in various ways for various purposes; e.g., intravenously, intramuscularly, subcutaneously, orally, intravaginally, rectally, buccally, sublingually, topically, and in the form of sterile implants for prolonged action.
- sterile aqueous isotonic solutions are preferred for intravenous injection or infusion.
- sterile solutions or suspensions of the acid, salt, or ester form in aqueous or non-aqueous media are used for subcutaneous or intramuscular injection.
- Tablets, capsules, and liquid preparations such as syrups, elixirs, and simple solutions, with the usual pharmaceutical carriers are used for oral or sublingual administra tion.
- suppositories prepared as known in the art are used for rectal or vaginal administration.
- tissue implants a sterile tablet or silicone rubber capsule or other object containing or impregnated with the substance is used.
- PGF a and PGF B are prepared by carbonyl reduction of PGE PGE has the following structure:
- each of the novel PGF (1 and PGF' 3 acid and ester analogs of formulas l-XXIX is prepared by carbonyl reduction of the corresponding PGE analog. Each such reduction gives a mixture of the corresponding PGF and PGF [3 compounds.
- ring carbonyl reductions are carried out by methods known in the art for ring carbonyl reductions of known prostaglandins. See, for example, Bergstrom et al., Arkiv Kemi 19, 563 (1963), Acta Chem. Scand. 16, 969 (1962), and British Specification No. 1,097,553. Any reducing agent is used which does not react with carbon-carbon double bonds or ester groups.
- Preferred reagents are lithium (tri-tertbutoxy) aluminum hydride, the metal borohydrides, especially sodium potassium and zinc borohydrides, and the metal trialkoxy borohydrides, e.g., sodium trimethoxyborohydride.
- the mixtures of alpha and beta hydroxy reduction products are separated into the individual alpha and beta isomers by methods known in the art for the separation of analogous pairs of known isomeric prostaglandins. See, for example, Bergstrom et al., cited above, Granstrom et al., J. Biol. Chem. 240, 457 (1965), and Green et al., J. Lipid Research 5, 117 1964).
- separation methods are partition chromatographic procedures, both normal and reversed phase, preparative thin layer chromatography, and coun tercurrent distribution procedures.
- PGE, and PGE type reactants needed for these carbonyl reductions are known in the art. See, for example, Struijk et al., Rec. Trav. Chim. 85, 1233 1966).
- the other necessary PGE, and PGE type reactants are prepared by the process described in our copending application Ser. No. 345,852, filed Feb. 19, 1964, now US. Pat. No. 3,296,091. See also Kupiecki, Life Sciences 4, 1811 (1965), Struijk, cited above, and Nugteren et al., Rec. Trav. Chim. 85, 405 (1966).
- the process of our said US. Pat. No. 3,296,091 comprises aerobic incubation of various all-cis trienoic acids and tetraenoic acids of the same carbon content desired in the PGE type product with comminuted mammalian gland tissue or with the enzyme system contained therein, in a substantially aqueous medium. Sheep vesicular glands are especially preferred as tissues for thisprocess. As indicated in that patent, the trienoic or tetraenoic acid is cyclized and oxygenated by this process to give the desired PGE type compound.
- the adaptation consists of the use of the appropriately different reactant to introduce the desired carboxyl-terminated chain and, for the compounds of formulas X-XXIX, the use of the appropriately different reactant to introduce the desired methyl-terminated chain.
- the procedures and reactants are the same as used by Corey et al.
- the alkyl ester forms of the novel PGF analogs of this invention are prepared either by esterification of the corresponding PGF type ester intermediate. Esterification of the PGF type free acid or the PGE type free acid reactant is advantageously accomplished by interaction of said free acid with the appropriate diazohydrocarbon. For example, when diazomethane is used, the methyl esters are produced. Similar use of diazoethane, diazobutane. and l-diazo-2 -ethylhexane, for example, gives the ethyl, butyl, and 2-ethylhexyl esters, respectively.
- Esterification with diazohydrocarbons is carried out by mixing a solution of the diazohydrocarbon in a suitable inert solvent, preferably diethyl ether, with the acid reactant, advantageously in the same or a different inert diluent. After the esterification reaction is complete, the solvent is removed by evaporation, and the ester purified if desired by conventional methods, preferably by chromatography. It is preferred that contact of the acid reactants with the diazohydrocarbon be no longer than necessary to effect the desired esterification, preferably about one to about ten minutes, to avoid undesired molecular changes. Diazohydrocarbons are known in the art or can be prepared by methods known in the art. See, for example, Organic Reactions, John Wiley & Sons, Inc., New York, NY. Vol. 8, pp. 389-394 (1954).
- An alternative method for esterification of the carboxy] moiety of the PGE-type compound or PGEtype reactant comprises transformation of the free acid to the corresponding silver salt, followed by interaction of that salt with an alkyl iodide.
- suitable iodides are methyl iodide, ethyl iodide, butyl iodide, isobutyl iodide, tertbutyl iodide, and the like;
- the silver salts are prepared by conventional methods, for example, by dissolving the acid in cold dilute aqueous am-.
- novel formula I PGF type free acids are transformed to pharmacologically acceptable salts by neutralization with appropriate amounts of the corresponding inorganic or organic base, examples of which correspond to the cations and amines listed above.
- These transformations are carried out by a variety of procedures known in the art to be generally useful for the preparation of inorganic, i.e., metal or ammonium, salts, amine acid addition salts, and quaternary ammo nium salts. The choice of procedure depends in part upon the solubility characteristics of the particular salt to be prepared.
- the inorganic salts it is usually suitable to dissolve the acid in water containing the stoichiometric amount of a hydroxide, carbonate, or bicarbonate corresponding to the inorganic salt desired.
- a hydroxide, carbonate, or bicarbonate corresponding to the inorganic salt desired.
- sodium hydroxide, sodium carbonate, or sodium bicarbonate gives a solution of the sodium salt of the prostanoic acid derivative.
- an amine salt acid is dissolved in a suit able solvent of either moderate or low polarity.
- a suit able solvent of either moderate or low polarity examples of the former are ethanol, acetone, and ethyl acetate.
- the latter examples of the latter are diethyl ether and benzene.
- At least a stoichiometric amount of the amine corresponding to the desired cation is then added to that solution. If the resulting salt does not precipitate, it is usually obtained in solid form by addition of a miscible diluent of low polarity or by evaporation. If the amine is relatively volatile, any excess can easily be removed by evaporation. It is preferred to use stoichiometric amounts of the less volatile amines.
- EXAMPLE 1 8-[ 3 01,5 a-dihydroxy-2B-( 3S-hydroxy-trans- 1 noneny)cyclopent-1a-yl]octanoic acid and 8-[3a,5B- dihydroxy-2/3-( 3S-hydroxy-trans- 1 -nonenyl )cyclopent-la-ylloctanoic acid.
- Formula 1 8-[ 3 01,5 a-dihydroxy-2B-( 3S-hydroxy-trans- 1 noneny)cyclopent-1a-yl]octanoic acid and 8-[3a,5B- dihydroxy-2/3-( 3S-hydroxy-trans- 1 -nonenyl )cyclopent-la-ylloctanoic acid.
- a solution of sodium borohydride (0.30 g.) in 1 ml. of water is added with stirring to a solution of 8-[30zhydroxy-2B-(3S-hydroxy-trans-l-nonenyl)-5-oxo cyclopent-1a-yl]-octanoic acid (600 mg.) in 25 ml. of absolute ethanol at C.
- the mixture is stirred 2.5 hours-at 0 C.
- 15 ml. of acetone is added and, minutes later, 3 volumes of water is added.
- the mixture is acidified with dilutehydrochloric acid and then extractedwith dichloromethane. The extract is washed with saturated aqueous sodium chloride solution, dried, and evaporated.
- the residue is chromatographed on silica gel, eluting with chloroform containing percent absolute ethanol.
- the eluate fractions containing the PGF type and PGF B type compounds as shown by thin layer chromatography are separately combined and evaporated to give, respectively, 8-[3a,5adihydroxy-2B-( 3S-hydroxy-transl -nonenyl )-cyclopent-la-yHoctanoic acid and 8-[3a,5B -dihydroxy-2fi- (3S-hydroxy-trans-l-nonenyl)-cyclopent-1ayl]octanoic acid.
- ethyl, and octyl esters of the same PGE type acid is transformed to the methyl, ethyl, and octyl esters of the same PGF, type and PGF B type acids.
- Example 1 of our said US. Pat. No. 3,296,091 is followed, but in place of the arachidonic acid reactant specified therein, there is used all-cis 9,12,15-docosatrienoic acid.
- a mixture of 8-[3ahydroxy-2B-(3-S-hydroxy-transl nonenyl)-5-oxocyclopent- 1 a-yl ]octanoic acid and 8-[ 3a,5adihydroxy-2,B-(3S-hydroxy-trans-1-nonenyl)-cyclopent-1a-yl]octanoic acid is produced and isolated as described in said patent.
- the components of this mixture are separated by silica gel chromatography and purified as described by Samuelsson, J, Biol. Chem. 238, 3229 (1963) for the separation and purification of PGE and PGFm.
- each of the PGE-type reactants used to prepared the PGF..-type .and PGF -type products of Example 2-18 is pre pared from the corresponding all-cis trienoic or tetraenoic acid.
- R is hydrogen, alkyl of one to 8 carbon atoms, or a pharmacologically acceptable cation.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
This invention is a group of new prostaglandin F analogs structurally similar to the natural prostaglandins F but differing therefrom in that the carboxy-terminated side chain of these new compounds contains more or fewer carbon atoms than the corresponding side chain of the natural prostaglandins F. These new prostaglandin F analogs are useful for a variety of pharmacological purposes, including anti-ulcer, inhibition of platelet aggregation, increase of nasal patency, and labor induction at term.
Description
United States Patent [191 Beahlll et a1.
1 1 Dec. 3, 1974 1 i PROSTAGLANDIN F2 B ANALOGS [75] Inventors: Philip E. Beal, Ill, Kalamazoo; Gunther S. Fonken, Charleston Township, Kalamazoo County; John E. Pike, Kalamazoo, all of Mich.
[731 Assignee: The Upjohn Company, Kalamazoo,
Mich.
[221 Filed: July 19, 1972 [211 App]. No.1 273,316
Related US. Application Data [63] Continuation-impart of Scr. No. 17,874, March 9, 1970, abandoned, which is a continuation-in-part of Ser, No 606,019, Dec. 30, 1966, abandoned, which is a continuation-in-part of Ser, No. 345,852, Feb. 19, 1964, Pat. No. 3,296,091.
[52] US. Cl 260/413, 260/211 R, 260/247.2 R, 260/268 R, 260/293.65, 260/326.3,
R, 260/468 D, 260/50l.1, 260/50115,
[51] Int. Cl. C07c 61/32, C07c 69/74 [58] Field of Search 260/514 D, 408 D, 408 Ca [56] References Cited UNlTED STATES PATENTS 3,706,789 12/1972 Bergstrom or al. 260/468 Primary ExaminerRobert Gerstl {57] ABSTRACT 2 Claims, N0 Drawings PROSTAGLANDIN F2 B ANALOGS CROSS REFERENCE TO RELATED APPLICATIONS DESCRIPTION OF THE INVENTION This invention relates to novel compositions of matter, and is more specifically concerned withnovel rganic compounds of the formula:
IIO
III
II OH I wherein R is hydrogen, alkyl of one to 8 carbon atoms, inclusive, or a pharmacologically acceptable cation, wherein a is zero or one, wherein n is 2, 3, 4, 5, 6, 7, or 8, wherein m is one, 2, 3, 4, or 5, and wherein indicates attachment of hydroxy to the ring in alpha or beta configuration with' the provisos that the compound contains l8, 19, 20, 2I, or 22 carbon atoms exclusive of R and that the chain does not contain 7 carbon atoms exclusive of R.
Included within the scope of formula I are compounds of the following formulas:
XVIII XIX XXI
II II (Ill; ((JIID UOOR ccuur cm u on 1|\ u XXIII no CL( 1 x Ull (Gim -000R n c Quorum u XX1\ 3O (:0
(cim r-C 0 o R C (CIIZ) CIIJI .u u XXV C:(. Cllz (CII2)7-COOR u oum cm I on n\ n' XXVI no [CHI (anal-000R I 11 o c112c113 In formulas II to XXIX, R is hydrogen, alkyl of one to 8 carbon atoms, inclusive, or a pharmacologically acceptable cation. In formula II and IV, 11 is 4 or 5. In formulas II and V, m is 7 or 8. In formulas VI and VIII, a is one or 2. In formulas VII and IX, b is 4 or 5. In formulas X and XIV, d is 7 'or 8 and p is one, 2, or 3. In formulas XI and XV, e is 3, 4, or 5. In formulas XVIII and XXIV,fis 4, 5 or 6 and q is one, 2', or 3. In formulas XIX and XXV, t is one or 2. In formulas XXII and XXVIII, v is'one or 2.
Compounds of formula I wherein indicates an alpha attachment of hydroxy to the ring are analogs of prostaglandin F (PGF, when a is zero and are analogs of prostaglandin F (IPGF a when a is one. Compounds of formula 1 wherein indicates a beta attachment of hydroxy to the ring are analogs of prostaglandin F (PGF p when a is zero and are analogs of prostaglandin F 5 (lPGF when a is one.
PGF a has the following structure:
(I O OH no" XXXI XXXll no 11 on PGF B has the following structure:
Molecules of PGF, PGE, B PGF a and PGF B and of each of the compounds encompassed by formulas l-XXIX each have several centers of asymmetry. Formulas l-XXlX are intended to represent o'ptically active compounds each with the same absolute configuration as optically active PGF, obtained from certain mammalian tissues, for example, sheep vesicular glands or human seminal plasma. See, for example, Bergstrom etal., Pharmacol. Rev. 20, l (1968) and references cited therein.
in formulas l-XXXlIl broken line attachments to the cyclopentane ring indicate substituents in alpha configuration, i.e., below the plane of the-cyclopentane ring. Heavy solid line attachments to the cyclopentane ring indicate substituents in beta configuration, i,e., above the plane of the cyclopentane ring. The configuration of the side chain hydroxy in each formula is S, as also specified in the above systematic name for PGF See Nature, 212, 38 (1966) for discussion of the seereochemistry of the prostaglandins.
Each ofthe known prostaglandins PGF PGF PGF a and PGF B have carbon atoms. A significant characteristic of these known prostaglandins is the seven carbon carboxyl-terminated side chain. Prostaglandins obtained from animal tissues always contain that length of that chain. In contrast, each of the novel prostaglandin analogs encompassed by formulas l-XXIX, exclusive of the possible carbon content of R, have a carboxyl-terminated chain shorter or longer than seven carbon atoms. Some of the novel compounds ofthis invention have the same total nu er of carbon atoms present in the known prostaglandins, while some have fewer and some have more carbon atoms, but in each novel compound, the carboxylterminated chain is different than in the known prostaglandins. It will be observed that compounds of formulas ll-lX each have the same methyl-terminated chain present in the known prostaglandins. Both the methylterminated chain and the carboxyl-terminated chain in compounds of formulas XXXIX differ from those chains in the natural prostaglandins.
' PGF, a PGF a PGF, ,3 and PGF B .and their esters and pharmacologically acceptable salts, are extremely potent in causi pg various biological-responses.
For that reason, these compounds are useful for pharmacological'purposes. See, for example, Bergstrom et al., Pharmacol. Rev. 20, 1 (1968), and references cited therein. A few of those biological responses are systemic arterial blood pressure lowering in the case of the PGF 3 compounds as measured, for example, in anesthetized (pentobarbital sodium) pentoliniumtreated rats with indwelling aortic and right heart cannulas; pressor activity, similarly measured, for the POP compounds; stimulation of smooth muscle as shown, for example, by tests on strips of quinea pig ileum, rabbit duodenum, or gerbil colon; potentiation of other smooth muscle stimulants; activity on the central ner vous system; decrease of blood platelet adhesiveness as shown by platelet-to-glass adhesiveness, and inhibitionof blood platelet aggregation and thrombus formation induced by various physical stimuli, e.g., arterial injury, and various biochemical stimuli, e.g., ADP, ATP, serotonin, thrombin, and collagen.
Because of these biological responses, these known prostaglandins are useful to study, prevent, control, or alleviate a wide variety of diseases and undesirable physiological conditions in .birds and mammals, includ- 1 ing humans, useful domestic animals, pets and zoological specimens, and in laboratory animals, for example, mice, rats, rabbits, and monkeys.
For example, these compounds are useful in mammals, including man, as nasal decongestants. For this purpose, the compounds are used in a dose range of about 10 ug. to about 10 mg. per ml. ofa pharmacologically suitable liquid vehicle or as an aerosol spray, both for topical application.
The PGF and PGF compounds are useful in the treatment of asthma. For example, these compounds are useful as bronchodilators or as inhibitors of mediators, such as SRS-A, and histamine which are released from cells activated by an antigen-antibody complex. Thus, these compounds control spasm and facilitate breathing in conditions such as bronchial asthma, bronchitis, brochiectasis, pneumonia and emphysema. For these purposes, these compounds are administered in a variety of dosage forms, e.g., orally in the form of tablets, capsules, or liquids; rectally in the form of suppositories; parenterally, subcutaneously, or intramuscularly, with intravenous administration being preferred in emergency situations; by inhalation in the form of aerosols or solutions for nebulizers; or by insufflation in the form of powder. Doses in the range of about 0.01 to 5 mg. per kg. of body weight are used 1 to 4 times a day, the exact dose depending on the age, weight, and condition of the patient and on the frequency and route of administration. For the above use these prostaglandins can be combined advantageously with other anti-asthmatic agents, such as sympathominetics (isoproterenol, phenylephrine, ephedrine, etc.)', xanthine derivatives (theophylline and aminophyllin); and cortico-steroids (ACTH and predinisolone). Regarding use of these compounds see South African Pat. No. 681,055.
The PGF and PGF ,3 compounds are useful whenever it is desired to inhibit platelet aggregation, to reduce the adhesive character of platelets, and to remove or prevent the formation of thrombi in mammals,- including man, rabbits, and rats. For example, these compounds are useful in the treatment and prevention of myocardial infarcts, to treat and prevent postoperative thrombosis, to promote patency of vascular the range of 0.004 to about 20 mg. per kg. of body weight per day are used, the exact dose depending on the age, weight, and condition of the patient or animal, and on the frequency and route of administration.
The PGF (1 and PGF [3 compounds are especially useful as additives to blood, blood products, blood substitutes, and other fluids which are used in artificial extra-corporeal circulation and perfusion ofisolated body portions, e.g., limbs and organs, whether attached to the original body, detached and being preserved or pre' pared for transplant, or attached to a new body. During these circulations and perfusions, aggregated platelets tend to block the blood vessels and portions of the circulation apparatus. This blocking is avoided by the presence of these compounds. For this purpose, the
compound is added gradually or in single or multiple portions to the circulating blood, to the blood of the donor animal, to the perfused body portion, attached or detached, to the recipient, or to two or all of those at a total steady-state dose of about 0.001 to 10 mg. per liter of circulating fluid. It is especially useful to use these compounds in laboratory animals, e.g., cats, dogs, rabbits, monkeys, and rats, for these purposes in order to develop new methods and techniques for organ and limb transplants.
The PGF [3 compounds are useful as hypotensive agents to reduce blood pressure in mammals, including man. For this purpose, the compounds are administered by intravenous infusion at the rate about 0.01 to about 50 pg. per kg. of body weight per minute or in single or multiple doses of about 25 to 500 pg. per kg. of body weight total per day.
The PGF B compounds also increase the flow of blood in the mammalian kidney, thereby increasing volume and electrolyte content of the urine. Therefore, these compounds are useful in managing cases of renal disfunction, especially those involving blockage of the renal vascular bed. Illustratively, the compounds are useful to alleviate and correct cases of edema resulting, for example, from massive surface burns, and in the management of shock. For these purposes, the compounds are preferably first administered by intravenous injection at a dose in the range 10 to 1000 pg. per kg. of body weight or by intravenous infusion at a dose in the range 0.1 to peg. per kg. of body weight per minute until the desired effect is obtained. Subsequent doses are given by intravenous, intramuscular, or subcutaneous injection or infusion in the range 0.05 to 2 mg. per kg. of body weight per day.
The PGF a and PGF 5 compounds are useful in place of oxytocin to induce labor in pregant female animals, including man, cows, sheep, and pigs, at or near term, or in pregnant animals with intrauterine death of the fetus from about 20 Weeks to term. For this purpose, the compound is infused intravenously at a dose 0.01 to 50 ug. per kg. of body weight per minute until or near the termination of the second stage of labor,
10 i.e., expulsion of the fetus. These compounds are especially useful when the female is one or more weeks post-mature and natural labor has not started, or 12 to 60 hours after the membranes have ruptured and natural labor has not yet started.
The PGF 0, and PGF [3 compounds are useful for controlling the reproductive cycle in ovulating female mammals, includinghumans and animals such as monkeys, rats, rabbits, dogs, cattle, and the like. For that purpose, PGF a for example, is administered systemically at a dose level in the range 0.0] mg. to about 20 mg. per kg. of body weight of the female mammal, advantageously during a span of time starting approximately at the time of ovulation and ending approximately at the time of menses or just prior to menses. Additionally, expulsion of an embryo or a fetus is accomplished by similar administration of the compound during the first third of the normal mammalian gestation period.
The novel PGF a and PGF 3 analogs encompassed by formulas I-XXIX each cause the same biological respouses described above for the corresponding known prostaglandins. Each of these new compounds is accordingly useful for the above-described pharmacological purposes, and is used for those purposes in. the same manner as described above.
The known PGF 0 and PGF 5 compounds'are all potent in causing multiple biological responses even at low doses. For example, PGF; 3 stimulates smooth muscle and also lowers blood pressure at the same low dose. Moveover, for many applications, these known prostaglandins havean inconveniently short duration of biological activity. In striking contrast, the novel Formula l-XXIX compounds are substantially more specific with regard to potency in causing prostaglandin-like biological responses, and have a substantially longer duration of biological activity. Therefore, each of these novel prostaglandin analogs is surprisingly and unexpectedly more useful than one of the corresponding above-mentioned known prostaglandins for at least one of the pharmacological purposes indicated above for the latter, because it has a different and narrower spectrum of biological activity than the known prostaglandins, and therefore is more specific in its activity and causes smaller and fewer undesired side effects than when the known prostag landin is used for the.
same purpose. Moreover, because of its piolonged activity, fewer and smaller doses of the novel prostaglandin analog can frequently be used to attain the desired result.
Another advantage of the novel compounds of this invention is that they are administered effectively orally, sublingually, intravaginally, buccally, or rectally, in addition to the usual intravenous, intramuscular, or subcutaneous injection or infusion methods indicated above for the uses of the known p'rostaglandins. These qualities are advantageous because they facilitate maintaining uniform levels of these compounds in the body with fewer, shorter, or smaller doses, and make possible self-administration by the patient.
The novel PGF (1 and PGF 5 compounds encompassed by formulas l-XXIX are used as described above in the free acid form, in alkyl ester form, or in pharmacologically acceptable salt form. When the ester form is used, any alkyl ester can be used wherein the alkyl moiety contains one to 8 carbon atoms, inolusive, i.e., methyl, ethyl, propyl, butyl, pentyl, hexyl,
heptyl, octyl, and isomeric forms thereof. However, it is preferred that the ester be alkyl of one to four carbon atoms, inclusive. Of those alkyl, methyl and ethyl are especially preferred for optimum absorption of the compound by the body or experimental animal system.
Pharmacologically acceptable salts of these formula l-XXlX compounds useful for the purposes described above are those with pharmacologically acceptable metal cations, ammonium, amine cations, or quaternary ammonium cations.
Especially preferred metal cations are those derived from the alkali metals, elg., lithium, sodium and potassium, and from the alkaline earth metals, e.g., magnesium and calcium, although cationic forms of other metals, e.g., aluminum, zinc, and iron, are within the scope of this invention.
Pharmacologically acceptable amine cations are those derived from primary, secondary, or tertiary amines. Examples of suitable amines are methylamine, dimethylamine, trimethylamine, ethylamine, dibutylamine, triisopropylamine, N-methylhexylamine, decylamine, dodecylamine, allylamine, crotylamine, cyclopentylamine, 'dicyclohexylamine, benzylamine, dibenzylamine, a-phenylethylamine, ,B-phenylethylamine, ethylenediamine, diethylenetriamine, and like aliphatic, cycloaliphatic, and araliphatic amines containing up to and including about 18 carbon atoms, as well as heterocyclic amines, e.g., piperidine, morpholine, pyrrolidine, piperazine, and lower-alkyl derivatives thereof, e.g., l-methylpiperidine, 4- ethylmorpholine, l-isopropylpyrrolidine, 2- methylpyrrolidine, 1,4-dimethylpiperazine, 2-
methylpiperidine, and the like, as well as amines containing watersolubilizing or hydrophilic groups, e.g., mono-, di-, and triethanolamine, ethyldiethanolamine, N-butylethanolamine, 2-amino-l-butanol, 2-amino-2- ethyl-1,3-propanediol, '2-amino-2-methyl-l-propanol, tris(hydroxymethyl)aminomethane, N- phenylethanolamine, N-(ptert-amylphenyl)diethanolamine, galactamine, N-methylglucamine, N- methylglucosamine, ephedrine, phenylephrine, epinephrine, procaine, and the like.
Examples of suitable pharmacologically acceptable quaternary ammonium cations are tetramethylammonium, tetraethylammonium, benzyltrimethylammonium, phenyltriethylammonium, and the like.
As discussed above, the compounds of formulas l-XXIX are administered in various ways for various purposes; e.g., intravenously, intramuscularly, subcutaneously, orally, intravaginally, rectally, buccally, sublingually, topically, and in the form of sterile implants for prolonged action.
For intravenous injection or infusion, sterile aqueous isotonic solutions are preferred. For that purpose, it is preferred because of increased water solubility to use the free acid form or the pharmacologically acceptable salt form. For subcutaneous or intramuscular injection, sterile solutions or suspensions of the acid, salt, or ester form in aqueous or non-aqueous media are used. Tablets, capsules, and liquid preparations such as syrups, elixirs, and simple solutions, with the usual pharmaceutical carriers are used for oral or sublingual administra tion. For rectal or vaginal administration, suppositories prepared as known in the art are used. For tissue implants, a sterile tablet or silicone rubber capsule or other object containing or impregnated with the substance is used.
It is known to prepare PGF, and PGF, 3 by carbonyl reduction of the prostaglandin known as PGE Similarly, PGF a and PGF B are prepared by carbonyl reduction of PGE PGE has the following structure:
no 11 on PGE; has the following structure:
In the same manner, each of the novel PGF (1 and PGF' 3 acid and ester analogs of formulas l-XXIX is prepared by carbonyl reduction of the corresponding PGE analog. Each such reduction gives a mixture of the corresponding PGF and PGF [3 compounds.
These ring carbonyl reductions are carried out by methods known in the art for ring carbonyl reductions of known prostaglandins. See, for example, Bergstrom et al., Arkiv Kemi 19, 563 (1963), Acta Chem. Scand. 16, 969 (1962), and British Specification No. 1,097,553. Any reducing agent is used which does not react with carbon-carbon double bonds or ester groups. Preferred reagents are lithium (tri-tertbutoxy) aluminum hydride, the metal borohydrides, especially sodium potassium and zinc borohydrides, and the metal trialkoxy borohydrides, e.g., sodium trimethoxyborohydride. The mixtures of alpha and beta hydroxy reduction products are separated into the individual alpha and beta isomers by methods known in the art for the separation of analogous pairs of known isomeric prostaglandins. See, for example, Bergstrom et al., cited above, Granstrom et al., J. Biol. Chem. 240, 457 (1965), and Green et al., J. Lipid Research 5, 117 1964). Especially preferred as separation methods are partition chromatographic procedures, both normal and reversed phase, preparative thin layer chromatography, and coun tercurrent distribution procedures.
Some of the PGE, and PGE type reactants needed for these carbonyl reductions are known in the art. See, for example, Struijk et al., Rec. Trav. Chim. 85, 1233 1966). The other necessary PGE, and PGE type reactants are prepared by the process described in our copending application Ser. No. 345,852, filed Feb. 19, 1964, now US. Pat. No. 3,296,091. See also Kupiecki, Life Sciences 4, 1811 (1965), Struijk, cited above, and Nugteren et al., Rec. Trav. Chim. 85, 405 (1966).
The process of our said US. Pat. No. 3,296,091 comprises aerobic incubation of various all-cis trienoic acids and tetraenoic acids of the same carbon content desired in the PGE type product with comminuted mammalian gland tissue or with the enzyme system contained therein, in a substantially aqueous medium. Sheep vesicular glands are especially preferred as tissues for thisprocess. As indicated in that patent, the trienoic or tetraenoic acid is cyclized and oxygenated by this process to give the desired PGE type compound. For example, use of all-cis 9,12,15-docosatrienoic acid thereby yields 8-l3a-hydroxy-2B-(3Shydroxy-trans-1- nonenyl)-5-oxo-cyclopent-1a-yl]octanoic acid.
The same process of our said U.S. Pat. No. 3,296,091 also produces some of the PGF type compound corresponding to the PGE type compound. For example, use of all-cis 9,12,15-docosatrienoic acid gives not only the PGE type analog mentioned above but also the corresponding PGF type compound, i.e., 8-[3oz,50zdihydroxy-2B-(3s-hydroxy-trans'l-noneyl)-cyclopentla-ylloctanoic acid. This mixture of PGE type and PGF type products is separated, and each component is purified, both by the procedures set forth in said patent, or by other procedures known in the art to be useful for separating mixtures of the known prostaglandins and purifying the individual compounds. In partic ular, advantage is taken of the greater polarity of the PGF type compound in comparison with the PGE type compound in these separations, using chromatography on acid washed silica gel, reversed phase partition chromatography, preparative thin layer chromatography, or countercurrent distribution, or a combination of those. Thus, this enzymatic conversion of all-cis trienoic and tetraenoic acids provides a second route to the novel PGF a analogs of this invention.
All-cis trienoic and tetraenoic acids necessary to produce the PGE type compounds corresponcind to the PGE type compounds of formula 1 are encompassed by the formula:
CH (CH ),,,(CH=CHCH ),.(CH ),,COOH wherein m is one, 2, 3, 4, or as defined above, x is 3 or4 (a 3), andy is one, 2, 3, 4, 5, 6, or 7 (n l), a and n being as defined above. All-cis acids of that formula are known in the art, or are prepared by methods known in the art, for example, by the method of Osbond et al., Chem. 1nd. (London) 1288 (1959) and J. Chem. Soc. (London) 2779 (1961 the necessary intermediate acetylenic alcohols being prepared by the method ofConia, Bull. Soc. Chim. France 22 [5], 1449 (1955), and transformed to the corresponding substituted propargyl bromides by reaction with phosphorus tribromide. See also van der Streen et al., Rec. Trav. Chem. 82, 1015 (1963).
Since our invention of the novel compounds of formulas 1XXIX, other methods have become available for making PGE PGE PGF, a and PGF; These methods can easily be adapted to make the novel PGF analogs of this invention or to make the PGE intermediates necessary for preparation of the novel PGF a and PGF [3 analogs of this invention by car bonyl reduction. See, for example, Corey et al., J. Am. Chem. Soc. 91, 535 (1969); ibid., 92, 397 (1970); ibid., 92, 2586 (1970). In each case, the adaptation consists of the use of the appropriately different reactant to introduce the desired carboxyl-terminated chain and, for the compounds of formulas X-XXIX, the use of the appropriately different reactant to introduce the desired methyl-terminated chain. Otherwise, the procedures and reactants are the same as used by Corey et al.
The alkyl ester forms of the novel PGF analogs of this invention are prepared either by esterification of the corresponding PGF type ester intermediate. Esterification of the PGF type free acid or the PGE type free acid reactant is advantageously accomplished by interaction of said free acid with the appropriate diazohydrocarbon. For example, when diazomethane is used, the methyl esters are produced. Similar use of diazoethane, diazobutane. and l-diazo-2 -ethylhexane, for example, gives the ethyl, butyl, and 2-ethylhexyl esters, respectively.
Esterification with diazohydrocarbons is carried out by mixing a solution of the diazohydrocarbon in a suitable inert solvent, preferably diethyl ether, with the acid reactant, advantageously in the same or a different inert diluent. After the esterification reaction is complete, the solvent is removed by evaporation, and the ester purified if desired by conventional methods, preferably by chromatography. It is preferred that contact of the acid reactants with the diazohydrocarbon be no longer than necessary to effect the desired esterification, preferably about one to about ten minutes, to avoid undesired molecular changes. Diazohydrocarbons are known in the art or can be prepared by methods known in the art. See, for example, Organic Reactions, John Wiley & Sons, Inc., New York, NY. Vol. 8, pp. 389-394 (1954).
An alternative method for esterification of the carboxy] moiety of the PGE-type compound or PGEtype reactant comprises transformation of the free acid to the corresponding silver salt, followed by interaction of that salt with an alkyl iodide. Examples of suitable iodides are methyl iodide, ethyl iodide, butyl iodide, isobutyl iodide, tertbutyl iodide, and the like; The silver salts are prepared by conventional methods, for example, by dissolving the acid in cold dilute aqueous am-.
monia, evaporating the excess ammonia at reduced pressure, and then adding the stoichiometric amount of silver nitrate.
The novel formula I PGF type free acids are transformed to pharmacologically acceptable salts by neutralization with appropriate amounts of the corresponding inorganic or organic base, examples of which correspond to the cations and amines listed above. These transformations are carried out by a variety of procedures known in the art to be generally useful for the preparation of inorganic, i.e., metal or ammonium, salts, amine acid addition salts, and quaternary ammo nium salts. The choice of procedure depends in part upon the solubility characteristics of the particular salt to be prepared. 1n the case of the inorganic salts, it is usually suitable to dissolve the acid in water containing the stoichiometric amount of a hydroxide, carbonate, or bicarbonate corresponding to the inorganic salt desired. For example, such use of sodium hydroxide, sodium carbonate, or sodium bicarbonate gives a solution of the sodium salt of the prostanoic acid derivative.
Evaporation of the water or addition of a watermiscible solvent of moderate polarity, for example, a lower alkanol or a'lower alkanone, gives the solid inorganic salt if that form is desired.
To produce an amine salt, acid is dissolved in a suit able solvent of either moderate or low polarity. Examples of the former are ethanol, acetone, and ethyl acetate. Examples of the latter are diethyl ether and benzene. At least a stoichiometric amount of the amine corresponding to the desired cation is then added to that solution. If the resulting salt does not precipitate, it is usually obtained in solid form by addition of a miscible diluent of low polarity or by evaporation. If the amine is relatively volatile, any excess can easily be removed by evaporation. It is preferred to use stoichiometric amounts of the less volatile amines.
EXAMPLE 1 8-[ 3 01,5 a-dihydroxy-2B-( 3S-hydroxy-trans- 1 noneny)cyclopent-1a-yl]octanoic acid and 8-[3a,5B- dihydroxy-2/3-( 3S-hydroxy-trans- 1 -nonenyl )cyclopent-la-ylloctanoic acid. (Formula I: a O, n 7, m
"A solution of sodium borohydride (0.30 g.) in 1 ml. of water is added with stirring to a solution of 8-[30zhydroxy-2B-(3S-hydroxy-trans-l-nonenyl)-5-oxo cyclopent-1a-yl]-octanoic acid (600 mg.) in 25 ml. of absolute ethanol at C. The mixture is stirred 2.5 hours-at 0 C. Then, 15 ml. of acetone is added and, minutes later, 3 volumes of water is added. The mixture is acidified with dilutehydrochloric acid and then extractedwith dichloromethane. The extract is washed with saturated aqueous sodium chloride solution, dried, and evaporated. The residue is chromatographed on silica gel, eluting with chloroform containing percent absolute ethanol. The eluate fractions containing the PGF type and PGF B type compounds as shown by thin layer chromatography are separately combined and evaporated to give, respectively, 8-[3a,5adihydroxy-2B-( 3S-hydroxy-transl -nonenyl )-cyclopent-la-yHoctanoic acid and 8-[3a,5B -dihydroxy-2fi- (3S-hydroxy-trans-l-nonenyl)-cyclopent-1ayl]octanoic acid.
Following the procedure-of Example 1, the methyl,
ethyl, and octyl esters of the same PGE type acid is transformed to the methyl, ethyl, and octyl esters of the same PGF, type and PGF B type acids.
Also following the procedure of Example 1, the free acid form and the methyl, ethyl, and octyl ester forms of the following PGF a type and PGF ,3 type compounds are each produced by carbonyl reduction of the corresponding PGE type free acids and methyl esters, reference being made to the various parameters of formula 1:
Example No. a n m 9 l 4 4 I0 I 5 4 l l l 2 5 12 l 7 I l3 1 5 l l4 I I 4 l5 0 5 3 16 l 2 3 I7 I 4 5 EXAMPLE l8 8-[ 3rx-hydroxy-2B-( 3S-hydroxy-transl -nonenyl 5-oxo-cyclopent-la-yl]octanoic acid.
The procedure of Example 1 of our said US. Pat. No. 3,296,091 is followed, but in place of the arachidonic acid reactant specified therein, there is used all-cis 9,12,15-docosatrienoic acid. A mixture of 8-[3ahydroxy-2B-(3-S-hydroxy-transl nonenyl)-5-oxocyclopent- 1 a-yl ]octanoic acid and 8-[ 3a,5adihydroxy-2,B-(3S-hydroxy-trans-1-nonenyl)-cyclopent-1a-yl]octanoic acid is produced and isolated as described in said patent. The components of this mixture are separated by silica gel chromatography and purified as described by Samuelsson, J, Biol. Chem. 238, 3229 (1963) for the separation and purification of PGE and PGFm.
Following the procedure of Example 18, each of the PGE-type reactants used to prepared the PGF..-type .and PGF -type products of Example 2-18 is pre pared from the corresponding all-cis trienoic or tetraenoic acid.
We claim:
1. A compound of the formula:
wherein R is hydrogen, alkyl of one to 8 carbon atoms, or a pharmacologically acceptable cation.
2. A compound according to claim 1 wherein R is hy-
Claims (2)
1. A COMPOUND OF THE FORMULA:
2. A compound according to claim 1 wherein R is hydrogen.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US00273316A US3852316A (en) | 1970-03-09 | 1972-07-19 | Prostaglandin f2 {62 {0 analogs |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1787470A | 1970-03-09 | 1970-03-09 | |
US00273316A US3852316A (en) | 1970-03-09 | 1972-07-19 | Prostaglandin f2 {62 {0 analogs |
Publications (1)
Publication Number | Publication Date |
---|---|
US3852316A true US3852316A (en) | 1974-12-03 |
Family
ID=26690433
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US00273316A Expired - Lifetime US3852316A (en) | 1970-03-09 | 1972-07-19 | Prostaglandin f2 {62 {0 analogs |
Country Status (1)
Country | Link |
---|---|
US (1) | US3852316A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4011338A (en) * | 1974-05-28 | 1977-03-08 | American Home Products Corporation | 15-methyl prostaglandin compounds having bronchodilating activity |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3706789A (en) * | 1958-05-28 | 1972-12-19 | Sune Bergstrom | Pgf{11 {60 |
-
1972
- 1972-07-19 US US00273316A patent/US3852316A/en not_active Expired - Lifetime
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3706789A (en) * | 1958-05-28 | 1972-12-19 | Sune Bergstrom | Pgf{11 {60 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4011338A (en) * | 1974-05-28 | 1977-03-08 | American Home Products Corporation | 15-methyl prostaglandin compounds having bronchodilating activity |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4116988A (en) | 16-Phenoxy prostaglandin E1 analogs | |
US3728382A (en) | 15-methyl and 15-ethyl prostaglandin analogs | |
US3962293A (en) | 13,14-Dihydro-16-fluoro prostaglandin F1 | |
US3984400A (en) | 11-Desoxy-16-aryl-ω-tetranorprostaglandins | |
US3847967A (en) | 15-lower alkoxy pgb compounds | |
US3759978A (en) | 5,6-trans pge{11 | |
US3845115A (en) | 15-lower alkoxy pgf compounds | |
US3852316A (en) | Prostaglandin f2 {62 {0 analogs | |
US3904679A (en) | 15-Methyl and 15-ethyl prostaglandin F{HD 2{331 {0 {B analogs | |
US3849487A (en) | Natural 15-methyl and ethyl-15-epi-pge1 | |
US3892795A (en) | 16-Methyl and 16,16 dimethyl PGA{HD 2 {B compounds | |
US3974195A (en) | 2A,2B-Dihomo-15-alkyl-PGF2.sub.α analogs | |
US3923861A (en) | 3-Oxa prostaglandin F{331 -type compounds | |
US3804890A (en) | 15-methyl and ethyl-15(r)-pgf2alpha | |
US3969381A (en) | 13,14-Dihydro-16-fluoro prostaglandin B1 analogs | |
US3969376A (en) | 13,14-Dihydro-16-fluoro prostaglandin E1 analogs | |
US3855270A (en) | 15-alkyl prostaglandins f{11 {301 | |
US3903131A (en) | 16 and 16,16-dimethyl PGE{HD 2{B | |
US3781325A (en) | 15-methoxy-pgf2a | |
US3923862A (en) | 4-Oxa prostaglandin {62 -type compounds | |
US3969379A (en) | 13,14-Dihydro-16-fluoro prostaglandin A1 analogs | |
US3929861A (en) | 16- AND 16,16-METHYL AND ETHYL SUBSTITUTED PGF{HD 1{B -type compounds | |
US3954833A (en) | 16,16-Methyl and ethyl substituted PGF2.sub.α compounds | |
US3821291A (en) | 5.6-trans pgb2 | |
US3770788A (en) | Silvated prostaglandins and process therefor |